The K.G. Jebsen Centre for B cell malignancies aim to define specific molecular and signaling aberrations in cells from different B-cell malignancies, investigate effector functions and specificities of T cells in patients, characterize the tumor microenvironment and identify beneficial T cell subsets with functional testing in vitro and in vivo, develop novel CARs and immunomodulating biologics to more efficiently recognize and kill cancer cells.
Results will guide the development and testing of novel immunotherapies and translate into clinical trials. Analysis of biological samples from trials will educate the lab research and allow patient stratification and prognostication. The K.G. Jebsen-Centre for B cell malignancies will bring together the whole spectrum of cutting-edge multidisciplinary research, from bench to bedside and address both immunotherapy and personalized medicine.
The K.G. Jebsen Centre for B cell malignancies converges research that has been published in the very best general science1-9 and clinical10-16 journals. The interdisciplinary Centre will enable highly competitive translational research, add research driven innovation, initiate new clinical trials and introduce frontline therapies that will benefit patients both nationally and internationally.
References
- Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92, doi:10.1038/nature08638 (2010).
- Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119, doi:10.1038/nature09671 (2011).
- Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120, doi:10.1038/nature11378 (2012).
- Muppidi, J. R. et al. Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma. Nature 516, 254-258, doi:10.1038/nature13765 (2014).
- Chan, L. N. et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542, 479-483, doi:10.1038/nature21076 (2017).
- Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679, doi:10.1126/science.1153629 (2008).
- Schjerven, H. et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nature immunology 14, 1073-1083, doi:10.1038/ni.2707 (2013).
- Rui, L. et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer cell 18, 590-605, doi:10.1016/j.ccr.2010.11.013 (2010).
- Khodadoust, M. S. et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature, doi:10.1038/nature21433 (2017).
- Johnson, P. et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. The New England journal of medicine 374, 2419-2429, doi:10.1056/NEJMoa1510093 (2016).
- Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. The New England journal of medicine 359, 2313-2323, doi:10.1056/NEJMoa0802885 (2008).
- Dave, S. S. et al. Molecular diagnosis of Burkitt's lymphoma. The New England journal of medicine 354, 2431-2442, doi:10.1056/NEJMoa055759 (2006).
- Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England journal of medicine 346, 1937-1947, doi:10.1056/NEJMoa012914 (2002).
- Ghanima, W. et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 385, 1653-1661, doi:10.1016/S0140-6736(14)61495-1 (2015).
- Bergh, J. et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356, 1384-1391 (2000).
- van Rhee, F. et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Oncology 15, 966-974, doi:10.1016/S1470-2045(14)70319-5 (2014).